Mechanism: Cyclic leuprolide reduces testosterone, inactivating thymic androgen receptors and enabling FOXN1-driven TEC and thymocyte regeneration. Readout: Readout: Thymic cellularity, naïve T-cell output, and TCR diversity significantly increase, while lean muscle and bone density are partially restored.
IF aged male C57BL/6 mice (20–24 months) are treated with a cyclic leuprolide acetate protocol — two sequential 4-week depot injection courses (75 µg/mouse subcutaneous sustained-release, separated by a 4-week off-period to allow partial gonadal recovery) — followed by calibrated sub-physiological dihydrotestosterone (DHT) add-back (delivered via 5 mg/kg/day subcutaneous micro-osmotic pump, targeting plasma DHT at ~10–15% of intact-male physiological levels, below the estimated thymic AR-suppressive threshold),
THEN thymic cellularity (total thymocyte counts, cortical and medullary TEC numbers by flow cytometry), thymic volume (micro-CT), peripheral naïve CD4⁺ and CD8⁺ T-cell output (sjTREC quantification by qPCR from peripheral blood), and TCR repertoire diversity (bulk TCRβ sequencing of splenocytes) will be significantly and durably elevated above age-matched intact controls at 12 weeks post-completion — with regeneration persisting through DHT add-back in at least 60% of the magnitude achieved at peak depletion — and systemic androgen-dependent endpoints (lean muscle mass, bone mineral density by DXA) will be partially restored compared to fully castrate controls,
BECAUSE of the following mechanistic chain:
-
Leuprolide depot induces pituitary GnRH receptor downregulation, causing sustained suppression of LH and FSH secretion, and consequently reducing testicular testosterone to castrate levels (<0.5 ng/mL) within 2–3 weeks of administration, as established in murine chemical castration models. (Activation of thymic regeneration in mice and humans following androgen blockade, Journal of Immunology, 2005 — referenced in Evidence Set)
-
Testosterone depletion removes tonic androgen receptor (AR) signaling in the thymic stromal compartment. AR is expressed selectively on thymic epithelial cells (TECs), fibroblasts, and endothelial cells — not on developing thymocytes — and its activation under normal physiology actively suppresses FOXN1 transcription, the master regulator of TEC identity and function, and downregulates Notch ligands including Delta-like 4 (Dll4) required for T-cell lineage commitment. (Evidence Set: Molecular Mechanisms section; Olsen et al., Immunology Today, 1998 — referenced in Evidence Set)
-
Relief of AR-mediated FOXN1 suppression permits thymic epithelial progenitor (TEP) re-activation and TEC regeneration. Following castration, TEPs proliferate and re-establish both cortical TEC (cTEC) and medullary TEC (mTEC) compartments, restoring the stromal microenvironment that supports sequential thymocyte maturation through DN → DP → SP stages. Absolute numbers of all thymocyte subsets recover toward young-mouse levels. (Reversal of age-related thymic involution with castration, Journal of Immunology — referenced in Evidence Set)
-
[SPECULATIVE] Cyclic depletion-recovery cycles cumulatively expand the TEP pool beyond what a single continuous depletion achieves. The 4-week off-period between leuproli...
SENS category: RepleniSENS
Community Sentiment
💡 Do you believe this is a valuable topic?
🧪 Do you believe the scientific approach is sound?
Voting closed
Sign in to comment.
Comments